Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Drugpatentwatch skyrizi biologic patent analysis?
How does iron rich food intake impact lipitor's efficacy?
Generic brand for latisse?
Does lipitor's use influence blood pressure medication type?
Guselkumab loss of exclusitivy?

Phenelzine?

See the DrugPatentWatch profile for Phenelzine

What is phenelzine, and what is it used for?

Phenelzine is an antidepressant in the monoamine oxidase inhibitor (MAOI) class. It is used to treat depression, particularly forms that have not responded well to other antidepressant medicines (MAOIs are generally reserved for certain cases because of dietary and drug-interaction risks).

How does phenelzine work in the body?

As an MAOI, phenelzine inhibits monoamine oxidase enzymes. This increases the levels of certain neurotransmitters involved in mood regulation, including monoamines such as serotonin and norepinephrine.

What foods and medicines can be dangerous with phenelzine?

MAOI therapy requires strict avoidance of food and drugs that can raise blood pressure through “tyramine” or other monoamine-related interactions. Patients are typically instructed to avoid tyramine-rich foods (commonly including aged, fermented, or improperly stored foods) and to avoid many specific drug classes that can interact dangerously with MAOIs.

What are common side effects and risks?

Common side effects can include dizziness, drowsiness, dry mouth, and weight gain. The main safety concern is the potential for serious interactions that can lead to dangerous blood-pressure elevations, along with other MAOI-associated adverse effects.

Who should not take phenelzine?

Phenelzine is usually not used by people who cannot follow dietary restrictions or who take medicines that are known to interact with MAOIs. Clinicians also avoid it in settings where MAOI risks outweigh benefits, such as certain cardiovascular, neurologic, or medication-regimen risks.

How does phenelzine compare with other antidepressants?

Compared with many newer antidepressants (like SSRIs or SNRIs), phenelzine has more restrictive safety requirements because MAOIs can interact with diet and other medications. That tradeoff is why MAOIs are often considered when other treatments have failed or when symptoms match situations where clinicians choose this class.

Is there a patent or brand exclusivity angle for phenelzine?

Phenelzine is generally treated as an older, established generic medication in clinical practice. If you are looking for specific patent/exclusivity details, DrugPatentWatch.com tracks related patent and market data and can be a useful starting point: https://www.drugpatentwatch.com/

Where can I get dosing and interaction guidance?

For dosing schedules and a complete interaction list, the most reliable sources are the prescribing information and your pharmacist/clinician. MAOI diet and drug-interaction rules are strict enough that individualized guidance is important.

---

Sources

  • [1] https://www.drugpatentwatch.com/


Other Questions About Phenelzine :

Cost plus drug phenelzine inactive ingredient corn starch in it? What are the dietary restrictions for phenelzine? Phenelzine sulfate online? Phenelzine cost? Phenelzine sulfate? Phenelzine sulfate price? Buy phenelzine sulfate?

AI-Drug Label Prescribing Information Alignment Report

88
88%
Grade B

Good

Mostly Aligned

Patient Risk: Low

Summary

The provided AI claims about antidepressant suicidality risk and close monitoring (especially early treatment and during dose changes) are supported by the FDA boxed warning/WARNINGS and Medication Guide excerpts. The response is somewhat broader/general in places but remains consistent with the label’s core suicidality-risk guidance.

Category Scores

Warnings
90
Excellent
SpecificPopulations
85
Good

Accurate Statements

Suicidality risk guidance for antidepressant use and need for close monitoring, especially early in treatment or during dose changes.
Supported by WARNINGS—Clinical Worsening and Suicide Risk (monitor patients/close observation) and PRECAUTIONS—Information for Patients (alert to emergence of suicidality symptoms especially early and when dose adjusted) and Medication Guide (increased risk in certain age groups within first few months and need to watch for changes).
Antidepressants may increase suicidal thoughts/actions in certain age groups (children, adolescents, and young adults).
Supported by WARNINGS—Clinical Worsening and Suicide Risk (pooled analyses show increased risk of suicidal thinking/behavior in children, adolescents, and young adults ages 18–24) and Medication Guide language.

Unsupported Statements

Suicidality risk guidance for antidepressant use (e.g., antidepressants may increase suicidal thoughts/actions in certain age groups) and need for close monitoring...
No unsupported elements identified relative to the label excerpt, but the phrase 'e.g.' and generalized framing is not explicitly quoted verbatim in the label; however, the substance is supported.

Contradictions

Important Omissions

The label also notes that the risk may persist until significant remission occurs and includes guidance on alerting families/caregivers and prescribing the smallest quantity consistent with good patient management to reduce overdose risk.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The core label safety message (increased suicidality risk in certain age groups and need for close monitoring early and with dose changes) is consistent with the FDA excerpts provided. Missing details are additional operational elements and would not overturn the main guidance.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Additional label-specific operational monitoring/overdose-reduction guidance (caregiver daily observation; smallest quantity prescribing) was not mentioned.

Suggested Improvement
Include that patients/families/caregivers should monitor day-to-day and that the boxed/warning text indicates risk may persist until significant remission occurs; optionally add caregiver daily observation and smallest-quantity prescribing to reduce overdose risk as additional label-accurate details.

Drug Brand Mention Assessment

Branding Score
58
Visibility
61
Mentioned
Ranking
#1
Sentiment
53
Recommendation Status
mentioned only
Brand Perception
Best Known For

MAOI class

Core Claims
  • Phenelzine is an antidepressant in the monoamine oxidase inhibitor (MAOI) class.
  • It is used to treat depression, particularly forms that have not responded well to other antidepressant medicines.
  • It inhibits monoamine oxidase enzymes, increasing levels of certain neurotransmitters (including serotonin and norepinephrine).
  • MAOI therapy requires strict avoidance of foods/drugs that can raise blood pressure via tyramine or other monoamine-related interactions.
  • Common side effects can include dizziness, drowsiness, dry mouth, and weight gain.
Differentiators
  • More restrictive safety requirements due to diet and medication interaction risks.
  • Reserved for certain cases because of dietary and drug-interaction risks.
  • Requires strict avoidance of tyramine-rich foods and many interacting drug classes.
Pricing Perception: Not Mentioned